Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5365
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease ; day:18 ; month:10 ; year:2018 ; pages:1-3
Bone marrow transplantation ; (18.10.2018), 1-3
- Creator
-
Kaloyannidis, Panayotis
- Contributor
-
Shaibani, Eshrak Al
Apostolidis, Ioannis
Kanfar, Solaf
Anezi, Khalid Al
Hashmi, Hani Al
SpringerLink (Online service)
- DOI
-
10.1038/s41409-018-0362-7
- URN
-
urn:nbn:de:101:1-2018112721570123606796
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kaloyannidis, Panayotis
- Shaibani, Eshrak Al
- Apostolidis, Ioannis
- Kanfar, Solaf
- Anezi, Khalid Al
- Hashmi, Hani Al
- SpringerLink (Online service)
Other Objects (12)
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial